Bg pattern

AQUIPTA 10 mg TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use AQUIPTA 10 mg TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

AQUIPTA 10 mg tablets

AQUIPTA 60 mg tablets

atogepant

This medicinal product is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of this leaflet includes information on how to report side effects.

Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is AQUIPTA and what is it used for
  2. What you need to know before you take AQUIPTA
  3. How to take AQUIPTA
  4. Possible side effects
  5. Storage of AQUIPTA
  6. Contents of the pack and other information

1. What is AQUIPTA and what is it used for

AQUIPTA contains the active substance atogepant. AQUIPTA is used to prevent migraine in adults who have at least 4 days of migraine per month.

AQUIPTA is thought to block the activity of the calcitonin gene-related peptide (CGRP) receptor family, which have been linked to migraine.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you take AQUIPTA

Do not take AQUIPTA

  • if you are allergic to atogepant or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Stop taking AQUIPTA and tell your doctor immediately if you experience any symptoms of an allergic reaction such as:

  • difficulty breathing
  • swelling of the face
  • rash, itching or hives

Some of these symptoms may occur within 24 hours after the first use. Sometimes they may occur several days after taking AQUIPTA.

Tell your doctor, pharmacist or nurse before you start taking AQUIPTA if you have severe liver problems.

Children and adolescents

Do not give this medicine to children or adolescents under 18 years of age, as the use of AQUIPTA in this age group has not been studied.

Other medicines and AQUIPTA

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines may increase the risk of side effects (see section 4).

The following list contains examples of medicines that may require your doctor to reduce the dose of AQUIPTA:

  • ketoconazole, itraconazole, clarithromycin, rifampicin (medicines used to treat fungal or bacterial infections);
  • ritonavir (medicine used to treat HIV);
  • cyclosporin (medicine that affects your immune system).

Pregnancy, breastfeeding and fertility

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

If you are pregnant, you should not take AQUIPTA. If you are a woman who could become pregnant, you should use adequate contraceptive methods during treatment with AQUIPTA.

If you are breastfeeding or planning to breastfeed, you should not take AQUIPTA. You and your doctor will decide whether to breastfeed or take AQUIPTA.

Driving and using machines

AQUIPTA may make you feel sleepy. Do not drive or use machines if you are affected.

AQUIPTA contains sodium

AQUIPTA 10 mg tablets

This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially “sodium-free”.

AQUIPTA 60 mg tablets

This medicine contains 31.5 mg of sodium (main component of cooking/table salt) per tablet. This is equivalent to 1.6% of the maximum recommended daily intake of sodium for an adult.

3. How to take AQUIPTA

Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.

How much to take

The recommended dose is 60 mg of atogepant once a day. Your doctor may tell you to take a lower dose if:

  • you are taking other medicines (mentioned in section 2);
  • you have severe kidney problems or are on dialysis.

How to take

AQUIPTA is taken by mouth. Do not break, crush, chew or split the tablet before swallowing. The tablets can be taken with or without food.

If you take more AQUIPTA than you should

If you take more tablets than you should, talk to your doctor. You may experience some of the side effects mentioned in section 4.

If you forget to take AQUIPTA

  • If you forget a dose, take it as soon as you remember.
  • If you forget during the whole day, skip the missed dose and take a dose as usual the next day.
  • Do not take a double dose to make up for forgotten doses.

If you stop taking AQUIPTA

Do not stop taking AQUIPTA without talking to your doctor first. Symptoms may come back if you stop treatment.

If you have any other questions on the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects

Stop taking AQUIPTA and contact your doctor immediately if you have any of the following symptoms, which may be part of a severe allergic reaction:

  • difficulty breathing
  • swelling of the face
  • rash, itching or hives

Other side effects

Tell your doctor if you notice any of the following side effects:

Common(may affect up to 1 in 10 people):

  • nausea (feeling sick);
  • constipation;
  • fatigue (tiredness);
  • sleepiness (drowsiness);
  • decreased appetite;
  • weight loss.

Uncommon(may affect up to 1 in 100 people):

  • increased levels of liver enzymes.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of AQUIPTA

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date is the last day of the month shown.

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and other information

What AQUIPTA contains

AQUIPTA 10 mg tablets

  • The active substance is atogepant. Each tablet contains 10 mg of atogepant.
  • The other ingredients are: copolymer of polyvinylpyrrolidone/vinyl acetate, polyethylene glycol succinate and vitamin E, mannitol, microcrystalline cellulose, sodium chloride, sodium croscarmellose, colloidal silicon dioxide and sodium stearyl fumarate (see section 2).

AQUIPTA 60 mg tablets

  • The active substance is atogepant. Each tablet contains 60 mg of atogepant.
  • The other ingredients are: copolymer of polyvinylpyrrolidone/vinyl acetate, polyethylene glycol succinate and vitamin E, mannitol, microcrystalline cellulose, sodium chloride, sodium croscarmellose, colloidal silicon dioxide and sodium stearyl fumarate (see section 2).

Appearance and packaging

AQUIPTA 10 mg tablets

The 10 mg tablet of AQUIPTA is a biconvex, round, white to off-white tablet with the inscription “A” and “10” on one side. It is available in packs containing 28 or 98 tablets.

AQUIPTA 60 mg tablets

The 60 mg tablet of AQUIPTA is a biconvex, oval, white to off-white tablet with the inscription “A60” on one side. It is available in packs containing 28 or 98 tablets.

Not all pack sizes may be marketed.

Marketing authorisation holder

AbbVie Deutschland GmbH & Co. KG

Knollstrasse

67061 Ludwigshafen

Germany

Manufacturer

AbbVie S.r.l

S.R. 148 Pontina Km 52 Snc

Campoverde di Aprilia, Latina 04011

Italy

You can request more information about this medicine from the local representative of the marketing authorisation holder:

België/Belgique/Belgien

AbbVie SA

Tél/Tel: +32 10 477811

Lietuva

AbbVie UAB

Tel: +370 5 205 3023

Text in Bulgarian language with contact information including company name and phone number

Luxembourg/Luxemburg

AbbVie SA

Belgique/Belgien

Tél/Tel: +32 10 477811

Ceská republika

AbbVie s.r.o.

Tel: +420 233 098 111

Magyarország

AbbVie Kft.

Tel.:+36 1 455 8600

Danmark

AbbVie A/S

Tlf: +45 72 30-20-28

Malta

Vivian Corporation Ltd.

Tel: +356 27780331

Deutschland

AbbVie Deutschland GmbH & Co. KG

Tel: 00800 222843 33 (gebührenfrei)

Tel: +49 (0) 611 / 1720-0

Nederland

AbbVie B.V.

Tel: +31 (0)88 322 2843

Eesti

AbbVie OÜ

Tel: +372 623 1011

Norge

AbbVie AS

Tlf: +47 67 81 80 00

Ελλάδα

AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.

Τηλ: +30 214 4165 555

Österreich

AbbVie GmbH

Tel: +43 1 20589-0

España

AbbVie Spain, S.L.U.

Tel: +34 91 384 09 10

Polska

AbbVie Sp. z o.o.

Tel.: +48 22 372 78 00

France

AbbVie

Tél: +33 (0) 1 45 60 13 00

Portugal

AbbVie, Lda.

Tel: +351 (0)21 1908400

Hrvatska

AbbVie d.o.o.

Tel + 385 (0)1 5625 501

România

AbbVie S.R.L.

Tel: +40 21 529 30 35

Ireland

AbbVie Limited

Tel: +353 (0)1 4287900

Slovenija

AbbVie Biofarmacevtska družba d.o.o.

Tel: +386 (1)32 08 060

Ísland

Vistor hf.

Sími: +354 535 7000

Slovenská republika

AbbVie s.r.o.

Tel: +421 2 5050 0777

Italia

AbbVie S.r.l.

Tel: +39 06 928921

Suomi/Finland

AbbVie Oy

Puh/Tel: +358 (0)10 2411 200

Κύπρος

Lifepharma (Z.A.M.) Ltd

Τηλ.: +357 22 34 74 40

Sverige

AbbVie AB

Tel: +46 (0)8 684 44 600

Latvija

AbbVie SIA

Tel: +371 67605000

Date of last revision of this leaflet:

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/.

To listen to or request a copy of this leaflet in , or to listen to it in

, contact the local representative of the marketing authorisation holder.

Online doctors for AQUIPTA 10 mg TABLETS

Discuss questions about AQUIPTA 10 mg TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for AQUIPTA 10 mg TABLETS?
AQUIPTA 10 mg TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in AQUIPTA 10 mg TABLETS?
The active ingredient in AQUIPTA 10 mg TABLETS is atogepant. This information helps identify medicines with the same composition but different brand names.
Who manufactures AQUIPTA 10 mg TABLETS?
AQUIPTA 10 mg TABLETS is manufactured by Abbvie Deutschland Gmbh & Co. Kg. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of AQUIPTA 10 mg TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether AQUIPTA 10 mg TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to AQUIPTA 10 mg TABLETS?
Other medicines with the same active substance (atogepant) include AQUIPTA 60 mg TABLETS, AIMOVIG 140 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN, AIMOVIG 70 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media